Nisa Investment Advisors LLC Takes $99,000 Position in VistaGen Therapeutics, Inc. (NASDAQ:VTGN)

Nisa Investment Advisors LLC acquired a new stake in VistaGen Therapeutics, Inc. (NASDAQ:VTGNGet Rating) during the 1st quarter, Holdings Channel reports. The institutional investor acquired 80,000 shares of the company’s stock, valued at approximately $99,000.

Several other hedge funds and other institutional investors have also modified their holdings of VTGN. Commodore Capital LP lifted its position in VistaGen Therapeutics by 65.2% during the 4th quarter. Commodore Capital LP now owns 8,464,999 shares of the company’s stock worth $16,507,000 after acquiring an additional 3,341,490 shares in the last quarter. Rafferty Asset Management LLC grew its stake in VistaGen Therapeutics by 98.8% during the 4th quarter. Rafferty Asset Management LLC now owns 490,295 shares of the company’s stock worth $956,000 after buying an additional 243,612 shares during the last quarter. New York State Common Retirement Fund boosted its position in VistaGen Therapeutics by 173.6% during the 4th quarter. New York State Common Retirement Fund now owns 367,052 shares of the company’s stock worth $716,000 after acquiring an additional 232,879 shares during the period. Epiq Partners LLC boosted its position in VistaGen Therapeutics by 15.9% during the 1st quarter. Epiq Partners LLC now owns 1,161,350 shares of the company’s stock worth $1,440,000 after acquiring an additional 159,000 shares during the period. Finally, Principal Financial Group Inc. lifted its holdings in shares of VistaGen Therapeutics by 299.9% in the fourth quarter. Principal Financial Group Inc. now owns 149,035 shares of the company’s stock valued at $291,000 after buying an additional 111,765 shares during the period. 67.75% of the stock is owned by institutional investors and hedge funds.

VistaGen Therapeutics Price Performance

VTGN stock opened at $0.14 on Friday. The business has a fifty day moving average price of $0.89 and a 200 day moving average price of $1.21. The stock has a market capitalization of $29.57 million, a price-to-earnings ratio of -0.60 and a beta of 1.06. VistaGen Therapeutics, Inc. has a fifty-two week low of $0.14 and a fifty-two week high of $3.26.

VistaGen Therapeutics (NASDAQ:VTGNGet Rating) last posted its quarterly earnings results on Thursday, June 23rd. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.03). VistaGen Therapeutics had a negative return on equity of 61.44% and a negative net margin of 4,306.76%. During the same period in the prior year, the business earned ($0.20) earnings per share. On average, equities analysts expect that VistaGen Therapeutics, Inc. will post -0.34 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. William Blair downgraded VistaGen Therapeutics from an “outperform” rating to a “market perform” rating in a report on Friday, July 22nd. Robert W. Baird lowered VistaGen Therapeutics from an “outperform” rating to a “neutral” rating in a research report on Friday, July 22nd. Jefferies Financial Group lowered VistaGen Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, July 22nd. Finally, Maxim Group downgraded VistaGen Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday.

Insider Activity

In other news, major shareholder Venrock Healthcare Capital Par sold 60,000 shares of the business’s stock in a transaction dated Tuesday, July 12th. The stock was sold at an average price of $0.89, for a total value of $53,400.00. Following the sale, the insider now directly owns 20,637,286 shares in the company, valued at $18,367,184.54. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 3.67% of the company’s stock.

VistaGen Therapeutics Profile

(Get Rating)

VistaGen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in preparation for Phase III development for the acute treatment of anxiety in adults with social anxiety disorder.

Featured Articles

Want to see what other hedge funds are holding VTGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for VistaGen Therapeutics, Inc. (NASDAQ:VTGNGet Rating).

Institutional Ownership by Quarter for VistaGen Therapeutics (NASDAQ:VTGN)

Receive News & Ratings for VistaGen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VistaGen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.